Spotlight: Nader Faults Amgen on Drug Research
Consumer activist Ralph Nader lashed out at Thousand Oaks-based Amgen Inc., saying it’s suppressing research that could improve its top-selling drug, Epogen, because it would hurt sales. In letters to President Clinton and Amgen executives, Nader charged that the company failed to support research that could improve Epogen’s effectiveness. Epogen is used to treat anemia in patients with kidney failure. It generates $1 billion in annual sales. An Amgen spokesman declined to comment.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
